Laxative

Current constipation medications don't provide relief for some patients with Chronic Idiopathic Constipation, per Gastroenterologist survey

Retrieved on: 
Tuesday, April 9, 2024
Adverse, Laxative, Gastrointestinal disease, Defecation, Patient, Human, American Journal, Weight loss, Constipation, News, Quality of life, Vibrant consonant, Hope, Invention, FDA

The survey of roughly 100 high-volume gastroenterology providers found that 74 percent of those interviewed are either unsure or positive that the medications they prescribe for patients with chronic constipation are not working.

Key Points: 
  • The survey of roughly 100 high-volume gastroenterology providers found that 74 percent of those interviewed are either unsure or positive that the medications they prescribe for patients with chronic constipation are not working.
  • Disrupting the U.S. $4.6 billion constipation treatment market, Vibrant Gastro’s first-in-class technology offers providers and patients with a new, non-pharmaceutical alternative to address this issue.
  • Patients track the progress of the treatment on their phone with an app to increase compliance, consistency and to monitor results.
  • A study presented at Digestive Disease Week in 2023 found significant symptomatic relief in patients and a substantially improved quality of life.

Orphan designation: Glycyl-L-2-methylprolyl-L-glutamic acid Treatment of Rett syndrome, 10/08/2015 Positive

Retrieved on: 
Tuesday, April 9, 2024
Eurostat, Diagnosis, Civil service commission, Speech, X chromosome, Brain, Medicine, MECP2, Disease, Laxative, Seizure, Nervous system, Patient, Chromosome, Committee, Knowledge, Constipation, Regulation, EMA, IRIS, Rett syndrome, Male, Intellectual disability, Clinical trial, European, COMP, Safety, European Commission, Marketing, Parent, Syndrome, DSM-IV codes, Anatomical pathology, Pharmaceutical industry

Orphan designation: Glycyl-L-2-methylprolyl-L-glutamic acid Treatment of Rett syndrome, 10/08/2015 Positive

Key Points: 


Orphan designation: Glycyl-L-2-methylprolyl-L-glutamic acid Treatment of Rett syndrome, 10/08/2015 Positive

Gastrointestinal Therapeutics and Diagnostics Technologies and Global Markets Report 2024-2028: Growing Trend toward Screening and Preventive Care and Adoption and Approval of Biological Drugs - ResearchAndMarkets.com

Retrieved on: 
Friday, April 5, 2024
Biotechnology, Pharmaceutical, Health, Medical Devices, Sanofi, Growth, Prevalence, AbbVie, Environment, Laxative, Incidence, Antacid, ESG, Gastroesophageal reflux disease, Malignancy, Constipation, Diarrhea, GI, GERD, Irritable bowel syndrome, Prescription, Inflammatory Bowel Diseases, Gastrointestinal disease, OTC, Therapy, Pancreatitis, IBS, Endoscopy, USD, PPI

The "Gastrointestinal Therapeutics and Diagnostics: Technologies and Global Markets" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Gastrointestinal Therapeutics and Diagnostics: Technologies and Global Markets" report has been added to ResearchAndMarkets.com's offering.
  • The Global Gastrointestinal Therapeutics and Diagnostics Market was valued at USD 86 Billion in 2023, and is expected to reach USD 122.5 Billion by 2028, rising at a CAGR of 7.30%.
  • This research study analyzes the GI diagnostics and therapeutics market, offers revenue forecasts, assesses future trends and provides strategic recommendations for the success of market participants.
  • This report estimates market data for 2022 (the base year) and forecasts for 2023 through 2028.

FASTEST GROWING BRANDS TO WATCH IN 2024 – RANKINGS RELEASED BY NUMERATOR

Retrieved on: 
Tuesday, January 16, 2024
Laxative, Habit, Weight loss, Growth

Methodology: Blended rank of household penetration growth and dollar sales growth between 2022 and 2023.

Key Points: 
  • Methodology: Blended rank of household penetration growth and dollar sales growth between 2022 and 2023.
  • Limited to brands with at least 5% household penetration in 2023.
  • Top Brands for GLP-1 Users in 2023.
  • As more consumers began using GLP-1 medications for diabetes management or weight loss in 2023, their buying habits shifted as well.

Human medicines European public assessment report (EPAR): Relistor, methylnaltrexone bromide, Date of authorisation: 01/07/2008, Revision: 19, Status: Authorised

Retrieved on: 
Tuesday, January 2, 2024
Patient, Medical Subject Headings, Diarrhea, Flatulence, Marketing, European Commission, Agency, INN, Constipation, Risk, Extrapyramidal system, Opioid, ATC, Bowel obstruction, International, Syringe, European, Spinal cord, Injection, Nausea, Language, Brain, Abdominal pain, Laxative, Naltrexone, Morphine, Disorder, Chronic pain, Select, Anatomy, Medicine, Palliative care, Dialysis, IIA, Skin, Medical device

Human medicines European public assessment report (EPAR): Relistor, methylnaltrexone bromide, Date of authorisation: 01/07/2008, Revision: 19, Status: Authorised

Key Points: 


Human medicines European public assessment report (EPAR): Relistor, methylnaltrexone bromide, Date of authorisation: 01/07/2008, Revision: 19, Status: Authorised

Human medicines European public assessment report (EPAR): Moventig, naloxegol, Date of authorisation: 07/12/2014, Revision: 16, Status: Authorised

Retrieved on: 
Tuesday, January 2, 2024
People, Medical Subject Headings, Peripheral, Diarrhea, Flatulence, Marketing, European Commission, Agency, INN, Constipation, Risk, Movement, Opioid, ATC, Pain, International, European, OIC, Spinal cord, Headache, Nausea, Language, Brain, Abdominal pain, Laxative, Cancer, Disorder, Tablet, Chronic pain, Select, Patient, Safety, Naloxone, Anatomy, Medicine, Bowel obstruction, Risk management, IIA, CHMP, Medical device

Human medicines European public assessment report (EPAR): Moventig, naloxegol, Date of authorisation: 07/12/2014, Revision: 16, Status: Authorised

Key Points: 


Human medicines European public assessment report (EPAR): Moventig, naloxegol, Date of authorisation: 07/12/2014, Revision: 16, Status: Authorised

Two-Thirds of Americans Are Living With Gut issues, Unaware of the Health Consequences

Retrieved on: 
Wednesday, May 24, 2023
Enema, Gut, Diet, Diabetes, Ipsos, Stroke, Food, Quality of life, Laxative, Woman, Grain boundary strengthening, Vegetable, Abdominal pain, MDVIP, Nutritional science, Yogurt, Bloating, Bacteria, Probiotic, Poultry farming, Birth control, Dietary supplement

BOCA RATON, Fla., May 24, 2023 /PRNewswire/ -- When it comes to gut health, Americans are not keeping theirs in check. A new study from MDVIP and Ipsos finds two-thirds of adults experience recurrent digestive symptoms like gas, bloating and abdominal pain, but few seek care from their doctor. The survey also reveals that most people are not aware of the importance of gut health and ways to improve it, with over half (52%) saying they are confused by the deluge of information on diet and nutrition and 85% of Americans failing a Gut IQ quiz.

Key Points: 
  • 2 in 3 Americans are unfamiliar with the term "gut microbiome," which are the trillions of bacteria living in the digestive tract.
  • 3 in 5 Americans don't know that an unhealthy gut can increase heart attack/stroke and dementia risk.
  • 71% of Americans don't know antibiotics can kill good gut bacteria in addition to the bad.
  • "Start with the dynamic duo of probiotics and prebiotics which work together in promoting the good bacteria in your gut.

FTC Milestones: Weighing in on weight loss cases

Retrieved on: 
Wednesday, May 10, 2023
Exercise, Constance Talmadge, Skeleton, Prejudice, Advertising, Hair, Section 5, Diet, Moonstone, Marketing, Method, Commission, Supreme Court of the United Kingdom, Weight loss, Laxative, Federal Trade Commission Act of 1914, Court, A Virtuous Vamp, Congress, Editorial, FTC, Commerce, Supreme court, Law of the United Kingdom, Hugo Black, Female, Wheeler–Lea Act, Birth control, Dietary supplement, Flapper

FTC Milestones: Weighing in on weight loss cases

Key Points: 

FTC Milestones: Weighing in on weight loss cases

Global Digestive Remedies Market 2023: Sector is Expected to Reach $22.53 Billion by 2028 at a CAGR of 3.3% - ResearchAndMarkets.com

Retrieved on: 
Monday, May 1, 2023
Health, Pharmaceutical, Proton, Online, Antacid, Prevalence, IBD, Internet, Overalls, Laxative, Ageing, Tablet, Constipation, Meal, Capsule, PPI, Market, Motion Sickness, Enzyme, IBS, Pharmacy, Heartburn, Distribution, Growth, Online and offline, Proton pump, Proton-pump inhibitor, Dietary supplement, GERD, Others, Powder

By Formulation: Based on the formulation, the global digestive remedies market can be segmented into four segments: Capsules, Tablets, Powder, and Others.

Key Points: 
  • By Formulation: Based on the formulation, the global digestive remedies market can be segmented into four segments: Capsules, Tablets, Powder, and Others.
  • By Distribution Channel: The global digestive remedies market can be divided into three segments based on distribution channel: Pharmacies & Drugstores, Online Providers, and Others.
  • By End User: The global digestive remedies market can be divided into two segments according to end user: Adult, and Pediatric.
  • In 2022, North America dominated the global digestive remedies market due to the high prevalence of digestive disorders.

Global Gastrointestinal Agents Industry Report to 2030: North America Dominates the Market - ResearchAndMarkets.com

Retrieved on: 
Tuesday, April 4, 2023
Health, Pharmaceutical, Inflammatory bowel disease, Incidence, Disorder, Laxative, A-DNA, Prevalence, Irritable bowel syndrome, Gastrointestinal disease, Extrapyramidal system, Pharmaceutical industry

Information such as market inclination insights and drivers, challenges and opportunities assists the readers for understanding the ongoing trends in the global gastrointestinal agents market.

Key Points: 
  • Information such as market inclination insights and drivers, challenges and opportunities assists the readers for understanding the ongoing trends in the global gastrointestinal agents market.
  • Tools such as market positioning of key players and attractive investment proposition provide the readers with insights on the competitive scenario of the global gastrointestinal agents market.
  • This report concludes with company profiles section that highlights major information about the key players engaged in global gastrointestinal agents market.
  • At present, North America dominates the global gastrointestinal agents market.